AI Analysis
AI-generated analysis. Always verify with the original filing.
Alterity Therapeutics received positive FDA feedback on clinical pharmacology and non-clinical elements for its ATH434 Phase 3 program in Multiple System Atrophy following a Type C Meeting.
Key Takeaways
1Alterity Therapeutics held Type C Meeting with FDA on ATH434 Phase 3 development program for MSA.
2FDA provided written feedback supporting clinical pharmacology and non-clinical development plans.
3Seeking FDA agreement on CMC and Phase 3 trial design.
4End-of-Phase 2 meeting on track for mid-year 2026.
5ATH434 showed clinically meaningful efficacy in Phase 2 randomized, double-blind, placebo-controlled trial in MSA participants.
6Positive data reported from open label Phase 2 trial in advanced MSA participants.